Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

807.19 +33.48 (+4.33%)
Official Closing Price Updated: 4:10 PM EDT, Jun 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival. 
Via Investor's Business Daily
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study. 
Via Investor's Business Daily
2 Top Stocks to Buy With Less Than $100
Via The Motley Fool
Exposures Product Safety
3 American Growth Giants to Invest in for the Long Haul
Via The Motley Fool
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
2 Beaten-Down Stocks to Buy on the Dip
Via The Motley Fool
Veru's Enobosarm Shows Muscle In Wegovy Combo Trial
Via Benzinga
P/E Ratio Insights for Eli Lilly
Via Benzinga
Smart Money Is Betting Big In LLY Options
Via Benzinga
Looking for a Blend of Growth and Dividend Stocks Amid Market Uncertainty? Consider This Low-Cost Vanguard ETF.
Via The Motley Fool
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position? 
Via Investor's Business Daily
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run
Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator. 
Via MarketBeat
Exposures Product Safety
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?
Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels. 
Via The Motley Fool
Eli Lilly's May Meltdown Is In History Books — Could June Seasonality Bring A Rebound?
Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% chance of closing higher. 
Via Benzinga
Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives
Eli Lilly to acquire SiteOne Therapeutics in a deal worth up to $1 billion, advancing the development of a potential non-opioid treatment for chronic pain. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Vanguard S&P 500 ETF: Is It Still a Core Portfolio Holding?
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
Exposures Artificial Intelligence US Equities
Xiaomi Reports Record Revenue, Profit In Q1 Led By Smartphone, EV Sales: Retail Stays Optimistic
Adjusted net profit jumped 64.5% YoY to hit a record high of RMB10.7 billion during the quarter. 
Via Stocktwits
Topics Artificial Intelligence Electric Vehicles
Exposures Artificial Intelligence Electric Vehicles
Eli Lilly To Acquire SiteOne Therapeutics For Up To $1B To Advance Pain Management Pipeline: But Retail’s Unconvinced
The $1 billion is inclusive of an upfront payment and subsequent payments upon achievement of certain regulatory and commercial milestones. 
Via Stocktwits
Why Novo Nordisk Stock Just Popped
President Trump has good news for Novo Nordisk investors, and more may be on the way. 
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Jim Cramer Says Rocket Is A 'Very Fine' Company, Recommends Buying This Health Care Stock
Via Benzinga
Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly
Via The Motley Fool
Topics Earnings Government World Trade
Exposures Financial Political Tariff
Prediction: These 2 Stocks Will Beat the Market in the Next Decade
Via The Motley Fool
Topics Government
Exposures Political
1 Brilliant Vanguard Index Fund to Buy Before It Soars Nearly 160%, According to a Wall Street Analyst
Via The Motley Fool
Topics ETFs Economy
Exposures Economy
2 Momentum Stocks with Impressive Fundamentals and 1 to Avoid
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
Exposures Product Safety
Value Investing Is Not Dead - It Just Got Smarter
Via Benzinga
3 Trades Members of Congress Are Making Right Now
Knowing what Congressional leaders are buying can give investors insight into future legislation that could benefit these companies 
Via MarketBeat
Topics ETFs Government
Exposures Political
Investing for the Long Term: 1 Unstoppable Vanguard ETF to Buy and Hold Forever
Via The Motley Fool
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
2 Growth Stocks to Own for Decades and 1 to Steer Clear Of
Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID... 
Via StockStory
Exposures COVID-19
5 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.